Government’s $650M National Drug Strategy Master Plan (NDSMP) will be thoroughly reviewed in March to evaluate aspects that have been implemented and those that require immediate attention, the Government Information Agency (GINA) reported.
“This year we will have the mid-term review of the National Drug Strategy Master Plan
